WHO ICTRP trial
Alternation in glucagon secretion by dietary intake after administration of…
JPRN-UMIN000021977 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000021977 |
|---|---|
| Public title | Alternation in glucagon secretion by dietary intake after administration of sodium glucose transporter-2 inhibitor. |
| Scientific title | Alternation in glucagon secretion by dietary intake after administration of sodium glucose transporter-2 inhibitor. - Alternation in glucagon secretion by Sodium glucose transporter-2 inhibitor |
| Primary sponsor | Kitasato University, School of Medicine |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not applicable |
| Countries | Japan |
| Conditions | Type 2(non-insulin dependent) diabetes mellitus |
| Interventions | Administration of sodium glucose transporter-2(SGLT-2) inhibitor, Luseogliflozin, and dose of Luseogliflozin is 25mg once a daily before breakfast, administration period of Luseogliflozin is 12wweks. |
| Registration date | Jan 5, 2016 |
| Target size | 20 |
| Registry page | center6.umin.ac.jp |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: